Rezdiffra Signals New Beginnings for NASH Drug Development

adicionou um novo artigo Outro

2025-07-09 09:59:05

The therapeutic landscape for non-alcoholic steatohepatitis (NASH) has undergone a dramatic transformation with Madrigal Pharmaceuticals' introduction of Rezdiffra (resmetirom), marking an unprecedented milestone in hepatic medicine. This revolutionary medication stands as the inaugural FDA-approved treatment specifically targeting NASH with fibrosis, fundamentally changing how clinicians...

0 Comentários 0 Compartilhamentos 94 Visualizações 0 Anterior